Hormone replacement therapy guideline
Executive Summary
Short-term hormone replacement therapy may not be as risky as once thought, according to an updated position statement by the North American Menopause Society. The new analysis, published in NAMS' online journal Menopause, says the risks and benefits of hormone replacement therapy change as women age. Authors say the therapy remains a viable option for the short-term treatment of moderate-to-severe vasomotor symptoms in recently menopausal women. However, women at increased risk for cardiovascular disease or breast cancer should avoid hormone therapy. The updated position statement will likely come as good news to Wyeth, which is still rebounding from a Women's Health Initiative study linking its Prempro product to increased risk of myocardial infarction, stroke and breast cancer (1"The Pink Sheet" Oct. 9, 2006, p. 8)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.